Utah Medical Products (FRA:UTM) Cyclically Adjusted Revenue per Share: €13.11 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UTM Utah Medical Products Inc FRA:UTM
73 GF Score
Price €58.50
GF Value €49.20
! 8 Warning Signs
View Full Analysis

What is Utah Medical Products Cyclically Adjusted Revenue per Share?

Utah Medical Products FRA:UTM -2.50% 73 Cyclically Adjusted Revenue per Share is €13.11 as of Jun. 2026. GuruFocus rates FRA:UTM with a GF Score™ of 73/100 and a GF Value™ of €49.20. The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Utah Medical Products's adjusted revenue per share for the three months ended in Jun. 2026 was €2.325. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €13.11 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Utah Medical Products's average Cyclically Adjusted Revenue Growth Rate was 1.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 1.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Utah Medical Products was 8.00% per year. The lowest was 1.60% per year. And the median was 5.80% per year.

As of today (2026-08-27), Utah Medical Products's current stock price is €58.50. Utah Medical Products's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €13.11. Utah Medical Products's Cyclically Adjusted PS Ratio of today is 4.46.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Utah Medical Products was 10.89. The lowest was 3.64. And the median was 6.88.


Utah Medical Products  (FRA:UTM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Utah Medical Products's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=58.50/13.11
=4.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Utah Medical Products was 10.89. The lowest was 3.64. And the median was 6.88.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Utah Medical Products Cyclically Adjusted Revenue per Share Related Terms


Utah Medical Products Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Utah Medical Products's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Utah Medical Products Cyclically Adjusted Revenue per Share Chart

Utah Medical Products Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.45 12.19 13.00 13.33 12.22

Utah Medical Products Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.26 11.83 12.22 13.14 13.11

FRA:UTM vs EMBC, SMTI, PDEX: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, Utah Medical Products's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Utah Medical Products Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Utah Medical Products's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Utah Medical Products's Cyclically Adjusted PS Ratio falls into.


FRA:UTM
73GF Score
Utah Medical Products Inc FRA:UTM
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Utah Medical Products Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Utah Medical Products's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.325/333.9520*333.9520
=2.325

Current CPI (Jun. 2026) = 333.9520.

Utah Medical Products Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.277 241.428 3.150
201612 2.244 241.432 3.104
201703 2.573 243.801 3.524
201706 2.583 244.955 3.521
201709 2.273 246.819 3.075
201712 2.301 246.524 3.117
201803 2.356 249.554 3.153
201806 2.500 251.989 3.313
201809 2.373 252.439 3.139
201812 2.296 251.233 3.052
201903 2.541 254.202 3.338
201906 2.807 256.143 3.660
201909 3.036 256.759 3.949
201912 2.846 256.974 3.699
202003 2.649 258.115 3.427
202006 2.133 257.797 2.763
202009 2.436 260.280 3.126
202012 2.702 260.474 3.464
202103 2.520 264.877 3.177
202106 2.862 271.696 3.518
202109 2.921 274.310 3.556
202112 3.112 278.802 3.728
202203 3.053 287.504 3.546
202206 3.480 296.311 3.922
202209 3.601 296.808 4.052
202212 3.535 296.797 3.978
202303 3.216 301.836 3.558
202306 3.263 305.109 3.571
202309 3.220 307.789 3.494
202312 3.112 306.746 3.388
202403 2.884 312.332 3.084
202406 2.736 314.175 2.908
202409 2.592 315.301 2.745
202412 2.583 315.605 2.733
202503 2.714 319.799 2.834
202506 2.658 322.561 2.752
202509 2.607 324.800 2.680
202512 2.415 324.054 2.489
202603 2.369 330.213 2.396
202606 2.325 333.952 2.325

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €13.11 mean?
Utah Medical Products (FRA:UTM) has a Cyclically Adjusted Revenue per Share of €13.11 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Utah Medical Products and its competitors.
Is Utah Medical Products' Cyclically Adjusted Revenue per Share too high?
Utah Medical Products' current Cyclically Adjusted Revenue per Share is €13.11. Overall, Utah Medical Products has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Utah Medical Products' Cyclically Adjusted Revenue per Share compare to EMBC and SMTI?
Utah Medical Products' Cyclically Adjusted Revenue per Share of €13.11 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Utah Medical Products and its competitors. Utah Medical Products's current Cyclically Adjusted Revenue per Share is €13.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Utah Medical Products stock overvalued right now?
Utah Medical Products (FRA:UTM) has a current Cyclically Adjusted Revenue per Share of €13.11. The stock's GF Value™ is €49.20, compared to a current price of €58.50 — trading 18.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €13.11. Utah Medical Products' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Utah Medical Products (FRA:UTM), the current Cyclically Adjusted Revenue per Share is €13.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Utah Medical Products (FRA:UTM) Overvalued in 2026?

Based on GuruFocus' analysis, Utah Medical Products stock appears to be overvalued. The current stock price of €58.50 is trading 18.9% above its estimated GF Value™ of €49.20.

Key valuation signals for FRA:UTM:

  • Cyclically Adjusted Revenue per Share: €13.11
  • GF Value™: €49.20 vs. price of €58.50 (18.9% above fair value)
  • GF Score™: 73/100 with 8 warning signs

No single metric tells the full story. See the FRA:UTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Utah Medical Products Business Description

Other Exchanges UTMD:USA
Address 7043 South 300 West, Midvale, UT, USA, 84047
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
73GF Score

Get the complete analysis for FRA:UTM

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€58.50
Price
€49.20
GF Value